Lisata acquires Marea Therapeutics, securing $225M financing to advance two mid-stage drugs
Lisata Therapeutics completed a stock-for-stock acquisition of biotech startup Marea Therapeutics.
The transaction includes a $225 million financing round led by existing backers such as Forbion, venBio and Third Rock Ventures, intended to fund the development of two mid-stage candidates targeting cardiovascular and endocrine diseases.
Post-deal ownership will see Marea shareholders holding roughly 60% of the combined company, Lisata shareholders just over 2%, and the investor group about 38%.
The deal follows Lisata’s earlier attempt to merge with Kuva Labs, which collapsed after Kuva could not secure financing, leading Lisata to cut most of its workforce and pursue strategic alternatives.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Lisata deal propels Marea’s drug pipeline to Wall Street”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that